Juvenile idiopathic arthritis (JIA) is an autoimmune, rheumatologic disease characterized by joint inflammation, pain, and stiffness; it encompasses multiple forms of chronic arthritis in children. The burden of the disease can be exacerbated by progressive deterioration from the arthritis, which affects some patients for life. Current treatment of JIA comprises corticosteroids, nonsteroidal anti-inflammatory drugs, and disease-modifying antirheumatic drugs (DMARDs)—including targeted biologics—which are prescribed to control pain, improve function, and reduce inflammation. Driven by the incentives of the Pediatric Research Equity Act and Best Pharmaceuticals for Children Act, the clinical pipeline in JIA is active, comprising oral and biologic DMARDs approved to treat adult rheumatological disorders—primarily rheumatoid arthritis. According to interviewed JIA experts, there is room for drugs with improved efficacy and/or a milder side-effect profile, to facilitate chronic therapy in the management of JIA.
- How large are the U.S. and EU5JIA patient populations, and how will their size change through 2026? How large are the key International League of Associations for Rheumatology (ILAR) subpopulations? What percentage of the JIA population receives prescription drug treatment?
- How are JIA patients diagnosed and managed? What are the key current therapies prescribed for JIA, and what drives their use?
- What are the key unmet needs in JIA, and to what extent will they be fulfilled by the therapies in the JIA pipeline?
- What clinical and commercial impact will emerging drugs have on the JIA therapy market through 2026?
- Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
- Primary research: Six country-specific interviews with pediatric rheumatologists.
- Epidemiology: Diagnosed incident cases of JIA, diagnosed and drug-treated prevalent cases of JIA, diagnosed prevalent cases of JIA by ILAR subtype and by age-group.
- Market forecast: Drug-level sales and patient share of key JIA therapies in 2026.
- Emerging therapies: Phase III: 3 drugs. Phase II: 1 drugs. Coverage of select Phase I/II and I products.
- Key companies: AbbVie, Amgen, Bristol-Myers Squibb, Genentech, Janssen, Novartis, Pfizer, Regeneron, Roche, Sanofi, Sobi, UCB.
- Key drugs: Humira, etanercept, Enbrel, infliximab, Remicade, tocilizumab, Actemra, RoActemra, anakinra, Kineret, canakinumab, Ilaris, abatacept, Orencia, certolizumab pegol, Cimzia, golimumab, Simponi, sarilumab, Kevzara, tofacitinib, Xeljanz, secukinumab, Cosentyx, sirukumab.